Fluoxetine: possible link to foetal cardiac defects

Infants exposed to fluoxetine during early gestation may have a slightly increased risk of congenital cardiac defects, the MHRA has advised. The increased risk, estimated to affect fewer than 2 in 100 pregnancies, is similar to that associated with paroxetine. Data are insufficient to draw conclusions about other SSRIs.

The possibility of cardiac defects in children exposed to fluoxetine in the womb should be weighed against the risks of untreated depression in pregnancy, which include low birth weight and preterm delivery. 

Further information: MHRA Drug Safety Update

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases